ArticleBiomedicines2024

Safety and Tolerability of a Shorter Agalsidase Beta Infusion Time in Patients with Classic or Later-Onset Fabry Disease.

Dominique P Germain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.